KLK1 Human, HEK
HEK293 cells
Greater than 95.0% as determined by SDS-PAGE.
Description
KLK1 Human Recombinant produced in HEK293 cells is a single, glycosylated, polypeptide chain containing 244 amino acids ( Pro19-Ser262 ).
KLK-1 is expressed with an 6 amino acid His tag at C-Terminus and purified by proprietary chromatographic techniques.
Product Specs
KLK1 Human Recombinant, produced in HEK293 cells, is a single, glycosylated polypeptide chain consisting of 244 amino acids (Pro19-Ser262). It is expressed with a 6-amino acid His tag at the C-terminus and purified using proprietary chromatographic techniques.
Supplied as a solution in 20mM TrisHCl, 150mM NaCl, 2mM CaCl2, with a pH of 8.
For short-term storage (up to 2-4 weeks), keep KLK1 refrigerated at 4°C. For extended storage, freeze at -20°C. Adding a carrier protein (0.1% HSA or BSA) is recommended for long-term storage. Avoid repeated freeze-thaw cycles.
Purity is determined to be greater than 95.0% using SDS-PAGE analysis.
HEK293 cells
Product Science Overview
Human recombinant KLK1 is often expressed in HEK 293 cells (Human Embryonic Kidney 293 cells), which are widely used in biotechnology for protein production due to their high transfection efficiency and ability to perform post-translational modifications . The recombinant form of KLK1 is typically produced with a 6-His tag at the C-terminus to facilitate purification .
KLK1 contains one peptidase S1 domain and exhibits preferential cleavage of Arg-|-Xaa bonds in small molecule substrates . It has a highly selective action to release kallidin (lysyl-bradykinin) from kininogen, involving the hydrolysis of Met-|-Xaa or Leu-|-Xaa bonds . The enzyme is glycosylated, which affects its migration during SDS-PAGE, resulting in an observed molecular weight of 40-45 kDa, despite its calculated molecular weight being 27.9 kDa .
KLK1 is involved in the generation of kinins, which are critical for vasodilation and long-term vascularization . It is present in various bodily fluids, including saliva, pancreatic juices, and urine . The enzyme’s activity is essential for maintaining blood flow and regulating blood pressure. Additionally, KLK1 has been used clinically to treat conditions associated with impaired local blood flow, such as acute ischemic stroke .
Due to its role in generating vasodilatory peptides, KLK1 has therapeutic potential in treating cardiovascular diseases, hypertension, and other conditions related to blood flow regulation . Its recombinant form, produced in HEK 293 cells, ensures a consistent and high-quality supply for research and clinical applications .
The recombinant KLK1 is typically lyophilized from a filtered solution containing Tris, CaCl2, and NaCl at pH 7.5, with mannitol or trehalose added as protectants . For reconstitution, it is recommended to use sterile PBS at pH 7.4 to achieve a concentration of 50 μg/mL. The solution can be stored at 2-8°C for up to one month or at -20°C for extended storage .
